Oncoinvent's rights issue concludes, underwriters cover remaining shares

Oncoinvent ASA announced the final results of its fully underwritten rights issue, raising gross proceeds of NOK 130 million through the issuance of 260,000,000 new shares. The subscription period, which ended on December 1, 2025, saw valid subscriptions for 180,902,224 shares, with the remaining 79,097,776 shares allocated to underwriters to ensure the issue was fully subscribed.

Notifications of allocated shares and payment instructions are expected today, December 2, 2025, with payment due by December 8, 2025. Subject to an extraordinary general meeting approval on December 5, 2025, and subsequent registration, the shares are anticipated to commence trading on the Oslo Stock Exchange around December 10, 2025.

Additionally, 31,199,997 new shares, priced at NOK 0.50 each, will be delivered to the underwriters as commission. ABG Sundal Collier ASA and DNB Carnegie acted as joint lead managers and joint bookrunners for the rights issue.